Literature DB >> 20529115

Codon 129 polymorphism and the E200K mutation do not affect the cellular prion protein isoform composition in the cerebrospinal fluid from patients with Creutzfeldt-Jakob disease.

Matthias Schmitz1, Markus Schlomm, Badrul Hasan, Michael Beekes, Eva Mitrova, Carsten Korth, Andreas Breil, Julie Carimalo, Joanna Gawinecka, Daniela Varges, Inga Zerr.   

Abstract

The cellular prion protein (PrP(c)) is a multifunctional, highly conserved and ubiquitously expressed protein. It undergoes a number of modifications during its post-translational processing, resulting in different PrP(c) glycoforms and truncated PrP(c) fragments. Limited data are available in humans on the expression and cleavage of PrP(c). In this study we investigated the PrP(c) isoform composition in the cerebrospinal fluid from patients with different human prion diseases. The first group of patients was affected by sporadic Creutzfeldt-Jakob disease exhibiting different PrP codon 129 genotypes. The second group contained patients with a genetic form of Creutzfeldt-Jakob disease (E200K). The third group consisted of patients with fatal familial insomnia and the last group comprised cases with the Gerstmann-Sträussler-Scheinker syndrome. We examined whether the PrP codon 129 polymorphism in sporadic Creutzfeldt-Jakob disease as well as the type of prion disease in human patients has an impact on the glycosylation and processing of PrP(c). Immunoblotting analyses using different monoclonal PrP(c) antibodies directed against various epitopes of PrP(c) revealed, for all examined groups of patients, a consistent predominance of the glycosylated PrP(c) isoforms as compared with the unglycosylated form. In addition, the antibody SAF70 recognized a variety of PrP(c) fragments with sizes of 21, 18, 13 and 12 kDa. Our findings indicate that the polymorphisms at PrP codon 129, the E200K mutation at codon 200 or the examined types of human transmissible spongiform encephalopathies do not exert a measurable effect on the glycosylation and processing of PrP(c) in human prion diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20529115     DOI: 10.1111/j.1460-9568.2010.07224.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  10 in total

1.  Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development.

Authors:  Sonia M Vallabh; Chloe K Nobuhara; Franc Llorens; Inga Zerr; Piero Parchi; Sabina Capellari; Eric Kuhn; Jacob Klickstein; Jiri G Safar; Flavia C Nery; Kathryn J Swoboda; Michael D Geschwind; Henrik Zetterberg; Steven E Arnold; Eric Vallabh Minikel; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-01       Impact factor: 11.205

2.  Codon 200 mutation of the prion gene: genotype-phenotype correlations.

Authors:  Peter K Panegyres; Judy G S Goh; Jack Goldblatt
Journal:  J Neurol       Date:  2012-05-15       Impact factor: 4.849

3.  Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry.

Authors:  Eric Vallabh Minikel; Eric Kuhn; Alexandra R Cocco; Sonia M Vallabh; Christina R Hartigan; Andrew G Reidenbach; Jiri G Safar; Gregory J Raymond; Michael D McCarthy; Rhonda O'Keefe; Franc Llorens; Inga Zerr; Sabina Capellari; Piero Parchi; Stuart L Schreiber; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2019-09-26       Impact factor: 5.911

4.  Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases.

Authors:  Anna Villar-Piqué; Matthias Schmitz; Ingolf Lachmann; André Karch; Olga Calero; Christiane Stehmann; Shannon Sarros; Anna Ladogana; Anna Poleggi; Isabel Santana; Isidre Ferrer; Eva Mitrova; Dana Žáková; Maurizio Pocchiari; Inês Baldeiras; Miguel Calero; Steven J Collins; Michael D Geschwind; Raquel Sánchez-Valle; Inga Zerr; Franc Llorens
Journal:  Mol Neurobiol       Date:  2018-07-30       Impact factor: 5.590

5.  Loss of prion protein leads to age-dependent behavioral abnormalities and changes in cytoskeletal protein expression.

Authors:  Matthias Schmitz; Catharina Greis; Philipp Ottis; Christopher J Silva; Walter J Schulz-Schaeffer; Arne Wrede; Katharina Koppe; Bruce Onisko; Jesús R Requena; Nambirajan Govindarajan; Carsten Korth; Andre Fischer; Inga Zerr
Journal:  Mol Neurobiol       Date:  2014-03-07       Impact factor: 5.590

6.  Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic.

Authors:  Matthias Schmitz; Elisabeth Ebert; Katharina Stoeck; André Karch; Steven Collins; Miguel Calero; Theodor Sklaviadis; Jean-Louis Laplanche; Ewa Golanska; Ines Baldeiras; Katsuya Satoh; Raquel Sanchez-Valle; Anna Ladogana; Anders Skinningsrud; Anna-Lena Hammarin; Eva Mitrova; Franc Llorens; Yong Sun Kim; Alison Green; Inga Zerr
Journal:  Mol Neurobiol       Date:  2015-05-07       Impact factor: 5.590

7.  Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis.

Authors:  Katharina Stoeck; Matthias Schmitz; Elisabeth Ebert; Christian Schmidt; Inga Zerr
Journal:  J Neuroinflammation       Date:  2014-10-15       Impact factor: 8.322

8.  Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients.

Authors:  Matthias Schmitz; Franc Llorens; Alexander Pracht; Tobias Thom; Ângela Correia; Saima Zafar; Isidre Ferrer; Inga Zerr
Journal:  Aging (Albany NY)       Date:  2016-11-14       Impact factor: 5.682

9.  Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases.

Authors:  Laia Lidón; Laura Urrea; Franc Llorens; Vanessa Gil; Ignacio Alvarez; Monica Diez-Fairen; Miguel Aguilar; Pau Pastor; Inga Zerr; Daniel Alcolea; Alberto Lleó; Enric Vidal; Rosalina Gavín; Isidre Ferrer; Jose Antonio Del Rio
Journal:  Cells       Date:  2020-05-19       Impact factor: 6.600

10.  Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients.

Authors:  Inga Zerr; Anna Villar-Piqué; Vanda Edit Schmitz; Anna Poleggi; Maurizio Pocchiari; Raquel Sánchez-Valle; Miguel Calero; Olga Calero; Inês Baldeiras; Isabel Santana; Gabor G Kovacs; Franc Llorens; Matthias Schmitz
Journal:  Biomolecules       Date:  2019-11-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.